EFC14771 Enrolling

Uncontrolled Asthma and/or Recurrent Severe Asthmatic Wheeze Research Trial (68-120 Weeks)


Treatment: Injection Age: 2 Years


Who Can Participate?

Children 2 to under 6 years of age inclusive, with uncontrolled asthma and/or recurrent severe asthmatic wheeze, may be eligible.

 

Inclusion Criteria:

      • Diagnosis of asthma or recurrent severe asthmatic wheeze
      • Asthma or recrurrent severe asthmatic wheeze not controlled with chronic ICS (inhaled corticosteroids) for at least 3 months with stable use of at least low dose ICS for ≥1 month prior to Screening Visit 1
      • Evidence of uncontrolled asthma and/or recurrent severe asthmatic wheeze

 

Participant Info:

      • No cost to participate or receive study treatment
      • Regular visits with study doctors who are familiar with uncontrolled asthma
      • Will receive investigational injected medication (active study drug) or placebo
      • Reimbursement for study-related expenses may be provided

 

How Long Will The Study Last?

      • Part A: about 68 weeks and involve about 20 study visits (including optional phone visits)
      • Part B (optional open-label extension): about 120 weeks and involve about 33 study visits (including optional phone visits)

Participating Locations

COUNTRY
country-icon
Canada

Participating Experts

No Doctors Found

You May Also Be Interested In

Similar Trials

No Similar Trials Found

The following information is from ClinicalTrials.gov

Last Update Posted: August 13, 2025

Official Title

A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Longterm Safety of Dupilumab in Children 2 to <6 Years of Age With Uncontrolled Asthma and/or Recurrent Severe Asthmatic Wheeze

ClinicalTrials.gov ID

NCT06191315

Sponsor

Sanofi

Study Description

  • Brief Summary:

    This is a parallel, Phase 3, 2-arm study to evaluate the efficacy and long-term safety of dupilumab treatment in children 2 to \<6 years of age with uncontrolled asthma and/or recurrent severe asthmatic wheeze. The study will be conducted in 2 parts. Part A will be a 52-week, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of dupilumab in children aged 2 to \<6 years old with uncontrolled asthma and/or recurrent severe asthmatic wheeze. At the end of Part A, all eligible participants will be offered participation in Part B, an optional open-label extension phase. Study details include: Part A: The study duration of part A will be up to 68 weeks consisting of a 4-week Screening, a 52week treatment period, and a 12-week post-treatment follow-up period. For participants who will chose to participate in Part B, the study duration will be up to 120 weeks (additional 52-week treatment period). Part B: For participants who will choose to participate in Part B, the study duration will be up to 120 weeks (Part A \[4-week Screening and a 52-week treatment period\] plus additional 52-week treatment period and a 12-week post-treatment follow-up period).

  • Condition or Disease:

    Wheezing, Asthma

  • Intervention/Treatment:

    Drug: Dupilumab Drug: Placebo
  • Phase:

    PHASE 3

  • Ages Eligible for Study:

    2 Years and 5 Years (CHILD)

  • Sexes Eligible for Study:

    ALL


Terms and Conditions – ClinicalTrials.gov
Purpose of ClinicalTrials.gov Database. The U.S. National Institutes of Health, Department of Health and Human Services, through its National Library of Medicine, has developed ClinicalTrials.gov to provide patients, family members, and members of the public current information about clinical research studies.



about-icon

Learn More About

Asthma - Pediatric

Learn More
2025 all rights reserved Probity Medical Research Inc
find a trial
General Registration

Can’t find a trial? Not sure which trial to choose? Complete a general registration and we’ll contact you with suitable trials.

Register
filter trials
Skip to content